Drug
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan: highest development phase Phase 3, developed by AstraZeneca, Daiichi Sankyo, United Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AstraZeneca, Daiichi Sankyo, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Trastuzumab Deruxtecan NCT07022483 | Phase 3 | Endometrial Cancer |
| Trastuzumab Deruxtecan NCT06819007 | Phase 3 | Ovarian Cancer |
| Trastuzumab Deruxtecan NCT05950945 | Phase 3 | Breast Cancer |
| Trastuzumab Deruxtecan NCT05048797 | Phase 3 | Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| Trastuzumab deruxtecan NCT05965479 | Phase 2 | Gastrooesophageal Cancer |
| Trastuzumab deruxtecan NCT06271837 | Phase 2 | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) |
| Trastuzumab deruxtecan NCT04482309 | Phase 2 | Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer |
| Trastuzumab-Deruxtecan (T-DXd) NCT06048718 | Phase 2 | Breast Cancer |
Latest
No recent events.
Follow Trastuzumab Deruxtecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.